A Randomised Controlled Trial Of A Bone Formation Stimulating Hormone To Reverse Osteonecrosis Of The Jaw In Cancer Patients
Grant number: 1030371 | Funding period: 2012 - 2015
Osteonecrosis of the jaw (ONJ) is debilitating and associated with drugs that increase bone strength and reduce the bone remodeling rate (bisphosphonates or denosumab). Up to 15% of patients with bone marrow cancer and 1 out of 952 patients with osteoporosis treated with bisphosphonates may get ONJ. This 8-week trial of subcutaneous teriparatide (a hormone that forms new bone) or placebo injections aims to promote resolution of ONJ, measured clinically and by x-ray, and improve quality of life.